Insider Buying: iTeos Therapeutics, Inc. (NASDAQ:ITOS) CFO Buys $38,650.00 in Stock

iTeos Therapeutics, Inc. (NASDAQ:ITOS) CFO Matthew Gall bought 5,000 shares of the business’s stock in a transaction that occurred on Tuesday, November 19th. The shares were purchased at an average price of $7.73 per share, for a total transaction of $38,650.00. Following the completion of the purchase, the chief financial officer now directly owns 65,429 shares of the company’s stock, valued at approximately $505,766.17. This trade represents a 8.27 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink.

iTeos Therapeutics Stock Up 3.9 %

Shares of iTeos Therapeutics stock opened at $8.16 on Friday. The firm has a market capitalization of $298.08 million, a P/E ratio of -2.59 and a beta of 1.39. iTeos Therapeutics, Inc. has a 52 week low of $7.54 and a 52 week high of $18.75. The firm’s 50 day moving average is $9.62 and its two-hundred day moving average is $13.87.

iTeos Therapeutics (NASDAQ:ITOS) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($1.05) EPS for the quarter, beating the consensus estimate of ($1.18) by $0.13. As a group, research analysts expect that iTeos Therapeutics, Inc. will post -3.46 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on ITOS. JPMorgan Chase & Co. cut their target price on shares of iTeos Therapeutics from $27.00 to $24.00 and set an “overweight” rating on the stock in a research note on Monday, August 12th. Wedbush restated an “outperform” rating and set a $25.00 target price on shares of iTeos Therapeutics in a research note on Tuesday, November 12th. HC Wainwright restated a “buy” rating and set a $46.00 target price on shares of iTeos Therapeutics in a research note on Friday, November 15th. Finally, Wells Fargo & Company began coverage on shares of iTeos Therapeutics in a research note on Tuesday, August 13th. They set an “overweight” rating and a $31.00 target price on the stock.

Hedge Funds Weigh In On iTeos Therapeutics

Hedge funds have recently modified their holdings of the business. nVerses Capital LLC grew its position in shares of iTeos Therapeutics by 212.5% during the third quarter. nVerses Capital LLC now owns 2,500 shares of the company’s stock worth $26,000 after acquiring an additional 1,700 shares during the last quarter. Point72 DIFC Ltd purchased a new position in shares of iTeos Therapeutics during the third quarter worth approximately $31,000. China Universal Asset Management Co. Ltd. grew its position in shares of iTeos Therapeutics by 60.4% during the third quarter. China Universal Asset Management Co. Ltd. now owns 7,024 shares of the company’s stock worth $72,000 after acquiring an additional 2,646 shares during the last quarter. Virtu Financial LLC purchased a new position in shares of iTeos Therapeutics during the third quarter worth approximately $102,000. Finally, Quest Partners LLC grew its position in shares of iTeos Therapeutics by 914.7% during the third quarter. Quest Partners LLC now owns 11,020 shares of the company’s stock worth $113,000 after acquiring an additional 9,934 shares during the last quarter. 97.16% of the stock is currently owned by hedge funds and other institutional investors.

About iTeos Therapeutics

Iteos Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.